Division B — Other Matters
DIVISION B Other Matters
TITLE I Extensions and Other Matters
SEC. 2102. Extension of Deadline to Promulgate Certain Regulations.
TITLE II Faa Extension
Subtitle A Federal Aviation Programs
SEC. 2201. Airport Improvement Program.
“(7) $842,076,502 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
SEC. 2202. Extension of Expiring Authorities; Miscellaneous Authorizations.
“(vi) $140,401,803 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
“(5) $9,803,278 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
SEC. 2203. Federal Aviation Administration Operations.
“(G) $2,995,027,322 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
; and
SEC. 2204. Air Navigation Facilities and Equipment.
“(7) $740,273,224 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
SEC. 2205. Research, Engineering, and Development.
“(16) $64,098,360 for the period beginning on October 1, 2023, and ending on December 31, 2023.”
SEC. 2206. Small Community Air Service.
Subtitle B Aviation Revenue Provisions
SEC. 2211. Expenditure Authority from Airport and Airway Trust Fund.
SEC. 2212. Extension of Taxes Funding Airport and Airway Trust Fund.
Subtitle C Expiring Counter-UAS Authorities
SEC. 2221. Protection of Certain Facilities and Assets from Unmanned Aircraft.
TITLE III Health and Human Services
Subtitle A Animal Drug and Animal Generic Drug User Fee Amendments
CHAPTER 1 Fees Relating to Animal Drugs
SEC. 2301. Short Title; Finding.
SEC. 2302. Definitions.
“(I) The activities necessary for implementation of the United States and European Union Mutual Recognition Agreement for Pharmaceutical Good Manufacturing Practice Inspections, and the United States and United Kingdom Mutual Recognition Agreement Sectoral Annex for Pharmaceutical Good Manufacturing Practices, and other mutual recognition agreements, with respect to animal drug products subject to review, including implementation activities prior to and following product approval.”
SEC. 2303. Authority to Assess and Use Animal Drug Fees.
“(III) an application for conditional approval under section 571 of a new animal drug for which an animal drug application submitted under section 512(b)(1) has been previously approved under section 512(d)(1) for another intended use.”
“(1) In general.—Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2024 through 2028, the fees required under subsection (a) shall be established to generate a total revenue amount of $33,500,000.”
“(1) Annual fee setting.—Not later than 60 days before the start of each fiscal year beginning after September 30, 2023, the Secretary shall—
“(A) establish for that fiscal year animal drug application fees, supplemental animal drug application fees, animal drug sponsor fees, animal drug establishment fees, and animal drug product fees based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and
“(B) publish such fee revenue amounts and fees in the Federal Register.”
“(ii) such adjustment shall be made for each fiscal year that the adjustment determined by the Secretary is greater than 3 percent, except for the first fiscal year that the adjustment is greater than 3 percent; and
“(iii) the Secretary shall publish in the Federal Register notice under paragraph (1) the amount of such adjustment and the supporting methodologies.”
“(4) Operating reserve adjustment.—
“(A) In general.—For fiscal year 2025 and each subsequent fiscal year, after the fee revenue amount established under subsection (b) is adjusted in accordance with paragraphs (2) and (3), the Secretary shall—
“(i) increase the fee revenue amount for such fiscal year, if necessary to provide an operating reserve of not less than 12 weeks; or
“(ii) if the Secretary has an operating reserve in excess of the number of weeks specified in subparagraph (C) for that fiscal year, the Secretary shall decrease the fee revenue amount to provide not more than the number of weeks specified in subparagraph (C) for that fiscal year.
“(B) Carryover user fees.—For purposes of this paragraph, the operating reserve of carryover user fees for the process for the review of animal drug applications does not include carryover user fees that have not been appropriated.
“(C) Number of weeks of operating reserves.—The number of weeks of operating reserves specified in this subparagraph is—
“(i) 22 weeks for fiscal year 2025;
“(ii) 20 weeks for fiscal year 2026;
“(iii) 18 weeks for fiscal year 2027; and
“(iv) 16 weeks for fiscal year 2028.
“(D) Publication.—If an adjustment to the operating reserve is made under this paragraph, the Secretary shall publish in the Federal Register notice under paragraph (1) the rationale for the amount of the adjustment and the supporting methodologies.”
“(4) Exemption from fees.—Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H.”
SEC. 2304. Reauthorization; Reporting Requirements.
SEC. 2305. Savings Clause.
SEC. 2306. Effective Date.
SEC. 2307. Sunset Dates.
CHAPTER 2 Fees Relating to Generic Animal Drugs
SEC. 2311. Short Title; Finding.
SEC. 2312. Authority to Assess and Use Generic New Animal Drug Fees.
“(4) Generic investigational new animal drug file fee.—
“(A) In general.—
“(i) New file request.—Each person that submits a request to establish a generic investigational new animal drug file on or after October 1, 2023, shall be assessed a fee as established under subsection (c).
“(ii) New submission to established file.—Each person that makes a submission to a generic investigational new animal drug file on or after October 1, 2023, where such file was established prior to October 1, 2023, shall be assessed a fee for the first submission on or after October 1, 2023, as established under subsection (c).
“(B) Payment.—
“(i) New file request.—The fee required by subparagraph (A)(i) shall be due upon submission of the request to establish the generic investigational new animal drug file.
“(ii) New submission to established file.—The fee required by subparagraph (A)(ii) shall be due upon the first submission to the generic investigational new animal drug file.
“(C) Exceptions.—
“(i) Terminating an existing generic investigational new animal drug file.—If a person makes a submission to the generic investigational new animal drug file to terminate that file, the person shall not be subject to a fee under subparagraph (A)(ii) for that submission.
“(ii) Transferring an existing generic investigational new animal drug file.—If a person makes a submission to the generic investigational new animal drug file to transfer that file to a different generic new animal drug sponsor, the person shall not be subject to a fee under subparagraph (A)(ii) for that submission.”
“(1) Annual fee setting.—The Secretary shall establish, not later than 60 days before the start of each fiscal year beginning after September 30, 2023, for that fiscal year—
“(A) abbreviated application fees that are based on the revenue amounts established under subsection (b), the adjustments provided under this subsection, and the amount of fees anticipated to be collected under subsection (a)(4) during that fiscal year;
“(B) generic new animal drug sponsor fees, and generic new animal drug product fees, based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and
“(C) a generic investigational new animal drug file fee of $50,000 for each request or submission described in subsection (a)(4)(A).”
“(ii) if the workload adjustment calculated by the Secretary under clause (i) exceeds 25 percent, the Secretary shall use 25 percent for the adjustment; and”
; and
“(d) Fee Waiver or Reduction.—The Secretary shall grant a waiver from, or a reduction of, one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication.”
“(5) Recovery of collection shortfalls.—The amount of fees otherwise authorized to be collected under this section shall be increased—
“(A) for fiscal year 2026, by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2024 falls below the amount of fees authorized for fiscal year 2024 under paragraph (3);
“(B) for fiscal year 2027, by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2025 falls below the amount of fees authorized for fiscal year 2025 under paragraph (3); and
“(C) for fiscal year 2028, by the amount, if any, by which the amount collected under this section and appropriated for fiscal years 2026 and 2027 (including estimated collections for fiscal year 2027) falls below the amount of fees authorized for such fiscal years under paragraph (3).”
“(8) Generic investigational new animal drug meeting request.—The term ‘generic investigational new animal drug meeting request’ means a request submitted by a generic new animal drug sponsor to meet with the Secretary to discuss an investigational submission for a generic new animal drug.”
“(I) The activities necessary for exploration and implementation of the United States and European Union Mutual Recognition Agreement for Pharmaceutical Good Manufacturing Practice Inspections, and the United States and United Kingdom Mutual Recognition Agreement Sectoral Annex for Pharmaceutical Good Manufacturing Practices, and other mutual recognition agreements, with respect to generic new animal drug products subject to review, including implementation activities prior to and following product approval.”
; and
“(12) Request to establish a generic investigational new animal drug file.—The term ‘request to establish a generic investigational new animal drug file’ means the submission to the Secretary of a request to establish a generic investigational new animal drug file to contain investigational submissions for a generic new animal drug.”
SEC. 2313. Reauthorization; Reporting Requirements.
SEC. 2314. Savings Clause.
SEC. 2315. Effective Date.
SEC. 2316. Sunset Dates.
Subtitle B Public Health Extenders
SEC. 2321. Extension for Community Health Centers, National Health Service Corps, and Teaching Health Centers That Operate Gme Programs.
“(I) $40,767,123 for the period beginning on October 1, 2023, and ending on November 17, 2023.”
SEC. 2322. Extension of Special Diabetes Programs.
“(E) $19,726,027 for the period beginning on October 1, 2023, and ending on November 17, 2023, to remain available until expended.”
“(E) $19,726,027 for the period beginning on October 1, 2023, and ending on November 17, 2023, to remain available until expended.”
Subtitle C Necessary Authorities To Respond to Threats
SEC. 2331. Extension of Authority to Make Certain Appointments of National Disaster Medical System Personnel.
SEC. 2332. Temporary Reassignment of State and Local Personnel During a Public Health Emergency.
SEC. 2333. Extension of National Advisory Committees.
Subtitle D Medicaid
SEC. 2341. Dsh Delay.
SEC. 2342. Mif Reduction.
Subtitle E Human Services
SEC. 2351. Extension of Child and Family Services Programs.
SEC. 2352. Sexual Risk Avoidance Education Extension.
SEC. 2353. Personal Responsibility Education Extension.
“(3) Exception.—Paragraphs (1) and (2) shall not apply with respect to any amount appropriated under subsection (f) for the period described in subsection (a)(1)(A).”
; and